{"product_id":"egf-receptor-antibody-egfr-bha17110361","title":"EGF Receptor Antibody \/ EGFR","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eEGF Receptor Antibody \/ EGFR is a research-use primary antibody intended for detection of \u003cstrong\u003eEGFR\u003c\/strong\u003e in experimental workflows. It is supplied in \u003cstrong\u003eAntigen affinity purified\u003c\/strong\u003e format. Key antibody attributes include Rabbit, Polyclonal, isotype Rabbit IgG. Applications listed for this product include WB, IHC-P, IF, FACS, Direct ELISA. Species reactivity (as provided): Human.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e EGFR (EGF Receptor) — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified — format can influence background, multiplexing compatibility, and downstream detection strategies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody identity:\u003c\/strong\u003e Rabbit, Polyclonal, isotype Rabbit IgG — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct notes (from provided description):\u003c\/strong\u003e The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. It is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2\/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). EGFR exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor alpha (TGFalpha). EGFR and its ligands are cell signaling molecules involved in diverse cellular functions, including cell proliferation, differentiation, motility, and survival, and in tissue development. Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including lung cancer and glioblastoma multiforme. In this latter case a more or less specific mutation of EGFR, called EGFRvIII is often observed.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWhere multiple assay formats are possible, align the antibody format, host\/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eIn this catalog, EGFR is positioned within \u003cstrong\u003eOncology \u0026amp; Angiogenesis, Cancer\u003c\/strong\u003e research contexts. For authoritative gene\/protein nomenclature, domains\/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003eHigher-plex and spatially resolved readouts (e.g., multiplex IF\/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host\/isotype and labeling strategies.\u003c\/li\u003e\n\u003cli\u003eGenetic perturbation controls (knockout\/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.\u003c\/li\u003e\n\u003cli\u003eReproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.\u003c\/li\u003e\n\u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eWB:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIHC-P:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIF:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFACS:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDirect ELISA:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTypical workflow themes:\u003c\/strong\u003e Western blot validation, IHC on FFPE tissue, IF\/ICC localization, Flow cytometry staining, ELISA binding assay, Specificity controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWorkflow notes:\u003c\/strong\u003e Validate EGFR by Western blot in cell\/tissue lysates (include controls), Detect EGFR by IHC in FFPE tissue sections (optimize antigen retrieval + dilution), Detect EGFR localization by IF\/ICC in cultured cells (optimi…\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWhen comparing conditions, consistent sample processing and appropriate negative\/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003eIsoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.\u003c\/li\u003e\n\u003cli\u003eSpecies and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.\u003c\/li\u003e\n\u003cli\u003eControl concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic\/orthogonal controls (e.g., KO\/KD, independent antibodies, or RNA measurements) when feasible.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eMonoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.\u003c\/p\u003e \u003c!-- Sources (internal): - UniProt Knowledgebase (UniProtKB) — UniProt Consortium — https:\/\/www.uniprot.org\/ - NCBI Gene — National Center for Biotechnology Information (NCBI) — https:\/\/www.ncbi.nlm.nih.gov\/gene\/ - Ensembl Genome Browser — EMBL-EBI — https:\/\/www.ensembl.org\/ - The Human Protein Atlas — Human Protein Atlas — https:\/\/www.proteinatlas.org\/ - Antibody validation concepts and controls (general guidance) — NIH \/ community resources — https:\/\/www.nih.gov\/ - MIQE\/experimental reporting \u0026 reproducibility (general) — Scientific community guidelines — https:\/\/www.equator-network.org\/ --\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53044847411565,"sku":"RQ5720","price":449.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.ebiohippo.com\/products\/egf-receptor-antibody-egfr-bha17110361","provider":"BioHippo","version":"1.0","type":"link"}